European Medicines Agency – Restriction to the Use of Modafinil
On 22 July, 2010 the European Medicines Agency recommended restricting the use of modafinil.
Doctors and patients are advised to use modafinil for treatment of narcolepsy only; all other indications to be removed from product information
The European Medicines Agency has recommended restricting the use of modafinil-containing medicines. The medicine should only be used to treat sleepiness associated with narcolepsy. Doctors and patients should no longer use the medicine for the treatment of idiopathic hypersomnia, excessive sleepiness associated with obstructive sleep apnoea and chronic shift work sleep disorder.
The review by the Agency’s Committee for Medicinal Products for Human Use (CHMP) was initiated because of a number of safety concerns, relating to psychiatric disorders, skin and subcutaneous tissue reactions as well as significant off-label use and potential for abuse.
On the basis of the available data the Committee concluded that the benefits of these medicines only outweighed their risks in the therapeutic indication narcolepsy, a chronic sleep disorder characterised by excessive daytime sleepiness. For all other indications the Committee found that the risk for development of skin or hypersensitivity reactions and neuropsychiatric disorders outweighed the evidence for clinically important efficacy. Therefore, the Committee concluded that all other indications should be withdrawn from the marketing authorisations of these medicines.
The SMC Advice has been removed from the website
- Medicine name:
- Modafinil (Provigil®)
- SMC ID:
- Excessive sleepiness associated with obstructive sleep apnoea / hypopnoea syndrome
- Pharmaceutical company
- Cephalon UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Date advice published:
- 13 June 2005
The European Medicines Agency has restricted the use of Modafinil
On 22 July 2010 the European Medicines Agency recommended restricting the use of modafinil. Doctors and patients are advised to use modafinil for treatment of narcolepsy only; all other indications to be removed from product information.